NCT06448403 Multimodal Assesment of Alzheimer Patients
| NCT ID | NCT06448403 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Norwegian University of Science and Technology |
| Condition | Mild Cognitive Impairment |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2030-12-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2024-07-01 with a primary completion date of 2030-12-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD). The main questions the study aims to answer are: 1. What findings can be used to earlier detect patients that will develop Alzheimers? 2. Which differences are seen between healthy and cognitively impaired patients? 3. Which differences are seen between patients with Alzheimers disease? Participants will undergo: * Cognitive tests * Magnetic resonance imaging (MRI) * Electroencephalography (EEG) * Blood sample collection * Fecal sample collection * A randomized group will undergo polysomnography analysis.
Eligibility Criteria
Inclusion Criteria: * MCI and AD according to relevant ICD-criterias. * Control cohort is age and gender matched with other cohorts. Exclusion Criteria: * Uneligibility for any of the planned neuroimagery devices (MRI, EEG) * AD diagnosis before the age of 65 (Early-onset AD). * Brain tumor * Traumtic head injury * Earlier neurosurgery * Other neyrodegenerative diseases (i.e Parkinson and ALS) * Diseases related to inflammation and auto-immunity (i.e MS)
Contact & Investigator
Axel Sandvig, Prof., MD, PhD
PRINCIPAL INVESTIGATOR
Norwegian University of Science and Technology (NTNU) & St. Olavs Hospital, Trondheim University Hospital
Frequently Asked Questions
Who can join the NCT06448403 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Mild Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06448403 currently recruiting?
Yes, NCT06448403 is actively recruiting participants. Contact the research team at axel.sandvig@ntnu.no for enrollment information.
Where is the NCT06448403 trial being conducted?
This trial is being conducted at Trondheim, Norway.
Who is sponsoring the NCT06448403 clinical trial?
NCT06448403 is sponsored by Norwegian University of Science and Technology. The principal investigator is Axel Sandvig, Prof., MD, PhD at Norwegian University of Science and Technology (NTNU) & St. Olavs Hospital, Trondheim University Hospital. The trial plans to enroll 60 participants.